Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Oh, Sang-Min | - |
dc.contributor.author | Chang, Mi-Yoon | - |
dc.contributor.author | Song, Jae-Jin | - |
dc.contributor.author | Rhee, Yong-Hee | - |
dc.contributor.author | Joe, Eun-Hye | - |
dc.contributor.author | Lee, Hyun-Seob | - |
dc.contributor.author | Yi, Sang-Hoon | - |
dc.contributor.author | Lee, Sang-Hun | - |
dc.date.accessioned | 2022-07-15T22:58:59Z | - |
dc.date.available | 2022-07-15T22:58:59Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2015-05 | - |
dc.identifier.issn | 1757-4676 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157315 | - |
dc.description.abstract | Use of the physiological mechanisms promoting midbrain DA (mDA) neuron survival seems an appropriate option for developing treatments for Parkinson's disease (PD). mDA neurons are specifically marked by expression of the transcription factors Nurr1 and Foxa2. We show herein that Nurr1 and Foxa2 interact to protect mDA neurons against various toxic insults, but their expression is lost during aging and degenerative processes. In addition to their proposed cell-autonomous actions in mDA neurons, forced expression of these factors in neighboring glia synergistically protects degenerating mDA neurons in a paracrine mode. As a consequence of these bimodal actions, adeno-associated virus (AAV)-mediated gene delivery of Nurr1 and Foxa2 in a PD mouse model markedly protected mDA neurons and motor behaviors associated with nigrostriatal DA neurotransmission. The effects of the combined gene delivery were dramatic, highly reproducible, and sustained for at least 1year, suggesting that expression of these factors is a promising approach in PD therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.title | Combined Nurr1 and Foxa2 roles in the therapy of Parkinson's disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Sang-Hun | - |
dc.identifier.doi | 10.15252/emmm.201404610 | - |
dc.identifier.scopusid | 2-s2.0-84929049040 | - |
dc.identifier.wosid | 000354135500002 | - |
dc.identifier.bibliographicCitation | EMBO MOLECULAR MEDICINE, v.7, no.5, pp.510 - 525 | - |
dc.relation.isPartOf | EMBO MOLECULAR MEDICINE | - |
dc.citation.title | EMBO MOLECULAR MEDICINE | - |
dc.citation.volume | 7 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 510 | - |
dc.citation.endPage | 525 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | PROTECTS DOPAMINERGIC-NEURONS | - |
dc.subject.keywordPlus | ALPHA-SYNUCLEIN | - |
dc.subject.keywordPlus | CELL-SURVIVAL | - |
dc.subject.keywordPlus | SUBCELLULAR-LOCALIZATION | - |
dc.subject.keywordPlus | PULMONARY INFLAMMATION | - |
dc.subject.keywordPlus | CEREBRAL-ISCHEMIA | - |
dc.subject.keywordPlus | MICROGLIAL CELLS | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordPlus | CNS | - |
dc.subject.keywordAuthor | Foxa2 | - |
dc.subject.keywordAuthor | gene therapy | - |
dc.subject.keywordAuthor | midbrain dopamine neuron | - |
dc.subject.keywordAuthor | Nurr1 | - |
dc.subject.keywordAuthor | Parkinson&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.identifier.url | https://www.embopress.org/doi/full/10.15252/emmm.201404610 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.